In a prospective study, we have investigated CD34 ؉ products can be reinfused safely after myeloablative treatment and result in sustained hematopoietic and immune recovery. The fact that all patients retained their specific measles immunity suggests that myeloablative treatment with reinfusion of highly purified CD34 ؉ PBPC is not immunoablative.
Autologous stem cell transplantation (ASCT) is increasingly being used for treatment of patients with disseminated lymphomas, such as follicular lymphoma (FL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (B-CLL). [1] [2] [3] [4] Whereas autologous bone marrow (BM) was used in earlier series, peripheral blood progenitor cells (PBPC) have widely replaced BM as the primary source of stem cells for autotransplantation. Like BM, PBPC autografts from patients with lymphoma frequently contain malignant cells as revealed by sensitive immunocytological or molecular techniques. 5 Although definite evidence is lacking, recent data suggest that tumor cells reinfused with the graft may contribute to relapse after autologous stem cell transplantation. 1, 6 Thus, strategies to reduce the tumor cell load of the autograft appear to be highly desirable in patients with disseminated lymphoma.
Positive selection of PBPC via the CD34 ϩ antigen allows effective reduction of contaminating lymphoma cells and its feasibility in the clinical setting has been proven. 7, 8 While the initial trials were undertaken with a selection device based on immunoadsorption, we used an immunomagnetic selection system (Isolex 300/300i, Nexell Therapeutics, Irvine, CA, USA). Preclinical and clinical data show that the Isolex system can be safely applied to human progenitor cells resulting in high purities and strongly reducing the tumor cell contamination of PBPC grafts. [9] [10] [11] In order to evaluate the safety and efficacy of the Isolex system in patients with low-grade lymphoma in a myeloablative setting, we have performed a prospective single center study including patients with FL, MCL, B-CLL, and immunocytoma. The objectives of this study were to demonstrate that reinfusion of Isolex-selected highly purified CD34 ϩ cells following myeloablative high-dose therapy allows complete and sustained hematopoietic engraftment. Since little is known about the effects of CD34 ϩ selection on long-term reconstitution of hematopoiesis and of the immune system, a major aim of this trial was to investigate parameters of hematopoietic and immune recovery during longer follow-up. A secondary objective was to assess the efficacy of the selection system to deplete lymphoma cells from PBPC grafts.
Materials and methods

Patients
Patients with a diagnosis of stage III or IV FL, MCL, immunocytoma (IC) or B-CLL according to the International Lymphoma Study Group classification 12, 13 were eligible if they were between 18 and 60 years old, were untreated or had received not more than one line of chemotherapy (maximum six cycles or 6 months of treatment), had an adequate performance status (Karnofsky у80%) and organ function, and had given written informed consent. Patients who had received previous radiotherapy or pretreatment were excluded. The trial including the informed consent forms was approved by the institutional ethical committee.
Between October 1994 and October 1996, 26 patients (six females; 20 males) were accrued. The median age was 49 (33-59) years. Diagnoses were FL in 10, MCL in seven, immunocytoma in two, and B-CLL in seven cases. Five patients were chemotherapy-naive, whereas 20 patients had been pretreated with 2-6 cycles (median, four) of the CHOP (cyclophosphamide, doxorubicine, vincristin, prednisolone, n = 13), CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone, n = 4), or COP (cyclophosphamide, vincristine, prednisolone, n = 3) regimens. A single patient had received five courses of chlorambucil monotherapy. Further details of the patient characteristics are given in Table 1 .
Immune recovery of the study patients was compared to 12 patients with indolent lymphoma receiving unselected PBPC during the same time period (controls, Table 1 ). These patients refused inclusion or met some exclusion criteria for the present study (ie previous radiotherapy or participation in a multicenter trial in which purging was not allowed).
Treatment protocol
After initial staging, eligible patients underwent one course of Dexa-BEAM chemotherapy for mobilization of PBPC. Further reduction of the tumor load was achieved by a second Dexa-BEAM cycle. If a state of 'minimal disease' was achieved (less than 1 ϫ 10 9 /l B cells in the peripheral blood, reduction of BM infiltration to less than 20% of the intertrabecular space, and residual lymphoma masses of less than 2 cm in diameter), patients proceeded to myeloablative therapy and PBPC reinfusion. After discharge, patients returned at 3, 6, and 12 months post-transplant to assess the following parameters: history of infections, performance status, physical examination, platelet count, BM biopsy, serum IgG level absolute numbers of CD3 ϩ ,
ϩ CD3 Ϫ and CD19 ϩ peripheral blood lymphocytes, and PCR-detectable molecular markers for residual disease (clonal rearrangement of the CDRIII region of the Ig heavy chain gene or t(14;18) translocation). In addition, serum IgA levels and the specific measles titer were recorded 12 months after transplant.
Administration of chemotherapy and progenitor cell collection
The Dexa-BEAM regimen included dexamethasone 3 ϫ 8 mg days 1-10, BCNU 60 mg/m 2 day 2, etoposide 75-250 mg/m 2 days 4-7, cytarabine 100 mg/m 2 q 12 h days 4-7, and melphalan 20 mg/m 2 day 3. 14 Patients received filgrastim (10 g/kg s.c. daily; Amgen, Munich, Germany) from day 8 after starting Dexa-BEAM until the last day of PBPC collection. Leukapheresis was performed as described previously, 15 provided that more than 20 ϫ 10 3 /ml circulating CD34 ϩ cells were present. A median of three (2-4) leukapheresis procedures was performed on consecutive days with a CS3000plus Blood Cell Separator (Baxter Deerfield, IL, USA). One or two collection products per patient were immediately subjected to CD34 ϩ selection without overnight storage or pooling (ie one separate run for each individual collection product).
Selection of CD34
ϩ cells
Separations for the first 19 patients were done with the semi-automated Isolex 300 device. The leukapheresis product was transferred to Fenwal 600 ml transfer bags, underwent a 10 min wash for reduction of platelets, and was resuspended in phosphate-buffered saline supplemented with 1% human serum albumin, 0.2% sodium citrate and 0.5% immunoglobulin followed by incubation with anti-CD34 antibody (9C5, Nexell) for 30 min at 4°C. After repeated washing for removal of unbound antibody, the sensitized cells were transferred to the 300 ml selection chamber of the Isolex device and incubated with sheep antimouse IgG1-coated paramagnetic Dynabeads (0.5 per mononuclear cell (MNC); M450 ST, Nexell) under gentle rotation for 30 min at room temperature. For the first nine patients, the total number of cells loaded on the chamber was restricted to a maximum of 150 ϫ 10 8 per run, which was increased to 600 ϫ 10 8 for the last 15 patients. Following bead rosetting, unlabeled cells were rinsed out by triple washing, while the rosetted target cells were retained in the selection chamber by the primary magnet of the Isolex device. Following a 15 min incubation with chymopapain (ChymoCell-T, Nexell) which releases all bound antibody with and without Dynabeads by cleavage of the 9C5 target epitope from the CD34 ϩ antigen, the suspension was exposed again to the primary magnet to allow separation of target cells from the detached beads. Target cells were washed twice using 50 ml polystyrene tubes, and counted and checked for viability using Neubauer chambers (Schreck, Hofheim, Germany) and trypan blue. After taking samples for flow cytometry, colony assays, and PCR, the final product was resuspended in freezing medium at a concentration of 5-20 ϫ 10 6 /ml, aliquoted in at least two portions and transferred into cryotubes (Nunc, Wiesbaden, Germany).
The last seven patients' products were immunoselected using the fully automated Isolex 300i apparatus. The procedure is basically similar to the one described above, but is less time-consuming and requires less intervention by the operator. It includes a spinning membrane and support module for cell washing without need for external centrifugation and employs a non-enzymatic stem cell releasing agent (PR34ϩ) instead of chymopapain for releasing the CD34 ϩ cells from the CD34 antibody/bead complexes. If less than 2 ϫ 10 6 /kg purified CD34 ϩ cells were retrieved with the first CD34 ϩ selection run, a second run was performed using the third leukapheresis product. An additional collection product containing at least 2 ϫ 10 6 /kg CD34 ϩ cells was stored unmanipulated as backup. Immunoselected CD34 ϩ cells and the unmanipulated backup underwent programmed freezing and were cryopreserved in liquid nitrogen until the day of reinfusion using cryopreservation medium consisting of RPMI 1640 supplemented with 10% autologous plasma, 30% hydroxyethyl starch, and 10% DMSO.
High-dose chemotherapy and progenitor cell reinfusion
Myeloablative therapy consisted of fractionated total body irradiation (TBI) 6 ϫ 2 Gy on 3 consecutive days followed by cyclophosphamide 2 ϫ 60 mg/kg. Daily filgrastim (5 g/kg) was administered to all patients from day ϩ1 until neutrophil recovery. Neutrophil recovery was defined as the first of 3 consecutive days with a neutrophil count Ͼ0.5 ϫ 10 9 /l; platelet recovery was defined as the first of 3 days with an unsupported platelet count Ͼ20 ϫ 10 9 /l. Patients were discharged from hospital after the white blood count had recovered (3 days above 1 ϫ 10 9 /l) in the absence of fever, parenteral nutrition or intravenous antibiotics. Supportive care was performed as described elsewhere. 16 Patients were kept on oral aciclovir (1000 mg/day) and cotrimoxazol (3 ϫ 960 mg twice a week) up to 6 months post-transplant as prophylaxis for Herpes zoster and Pneumocystis carinii infections, respectively. Cotrimoxazol was replaced by inhaled pentamidine (300 mg every 4 weeks) in patients with allergic skin rashes. Prophylactic immunoglobulin infusions were not given. 
Immunophenotypic analysis
PCR
Analysis of CDRIII rearrangements was carried out by twostep semi-nested PCR amplification using the oligonucleotide primers FR3A (5Ј-ACACG GC[C/T][G/C)] GTATT ACTGT-3Ј) for the FR3IgH region, LJH (5Ј-TGAGG AGACG GTGAC C-3Ј) for the JH-external region, and VLJH (5Ј-GTGAC CAGGG TNCCT TGGCC CCAG-3Ј) for the JH-internal region as previously described. 17 Negative and positive controls were included in each assay. CDRIII PCR amplification products were separated by polyacrylamide gel electrophoresis. Bands were visualized by silver staining.
PCR analysis of the major break point region (MBR) of t(14;18) was performed with primers P 28 (5Ј-GGTGA CAGG GTCCC TTGGC CCCAG-3Ј) for the JH-region, P27 (5Ј-GCAAT TCCGC ATTTA ATTCA TGGTA TTCAG GAT-3Ј) for bcl-2 MBR, and P3 (5Ј-CGTGG CCTGT TTCAA-3Ј) for bcl-2 MBR. Amplified t(14;18) DNA was analyzed in a 2% agarose gel stained with ethidium bromide and photographed under UV illumination.
As determined by serial dilution experiments, PCR allows detection of approximately one tumor cell in 10 3 -10 4 (CDRIII) or 10 5 normal cells (t (14;18) ).
Serology
Serum IgA and IgG levels were determined by nephelometry using standard antisera to human immunoglobulin subclasses (N Antiserum IgA, N Antiserum IgG, Behring Diagnostics, Marburg, Germany). The normal ranges of the assays used were 8-18 g/l for IgG and 0.9-4.5 g/l for IgA.
Immunofixation electrophoresis was performed with a commercially available reagent kit (Immunofix; Immuno, Vienna, Austria) according to the instructions of the manufacturer. The immunoprecipitates were visualized by protein staining. Measles titers were quantified using a commercially available test system (Enzygnost Antimeasles; Behring Diagnostics). This assay is an indirect sandwich ELISA employing microtiter plates coated with measles antigens derived from non-infected cells. Goat-antiheavy chain-specific antibody conjugated with peroxidase is utilized as detecting system. Tetramethylene benzidine dihydrochloride/H 2 O 2 is used as chromogen. Using the so called ␣-method, the assay gives quantitative results in IU/ml based on the WHO International Standard for antiMeasles-Serum, 1st International Standard Preparation. A rheumatoid factor absorption step is required for the detection of IgM antibodies. Serum samples were processed fully automatically with the Behring ELIS Processor III.
Statistical analysis
Employing NCSS software (NCSS, Kaysville, UT, USA), nonparametric Mann-Whitney tests were used to compare quantitative parameters between subgroups of patients. Qualitative parameters were analyzed with Chi-square test statistics. Significance levels were set at 0.05. Data were analyzed as of 31 January 1999.
Results
CD34
ϩ selection
All 26 patients included in the trial underwent PBPC mobilization with the first course of the Dexa-BEAM regimen. Two patients did not reach a level of 20 ϫ 10 3 /ml circulating CD34 ϩ cells in the peripheral blood and were excluded from CD34 ϩ selection. In the remaining 24 patients one or two selection runs were performed with unpooled leukapheresis products. For the first 17 patients (30 runs) the Isolex 300 device was used, whereas CD34 ϩ selection was performed with the Isolex 300i apparatus for the last seven patients (seven runs). Results are summarized in Table 2 . Highly enriched CD34 ϩ cell preparations were obtained with both devices. However, CD34
ϩ cell purity (median 98.8%) and recovery (46%) were significantly better with the 300i system compared to the 300 system (purity 89.2%; recovery 26%). This may indicate a superior performance of the 300i device, but it has to be taken into account that the absolute and relative input CD34 ϩ cell numbers were higher in the 300i group.
Purging efficacy
CD19
ϩ B cells could be demonstrated by flow cytometry in 26 of the 37 leukapheresis products prior to separation and were reduced to undetectable levels in the CD34 ϩ preparations in 15/26 cases (58%). The median B cell depletion in the 11 products with residual CD19 ϩ cells in the CD34 ϩ fraction was 3.2 log (0.6-5.1). A tumor-specific or clonal signal was present in 27/37 unprocessed products using t(14;18) or CDRIII PCR. In 10 of these 27 grafts (37%) the molecular marker disappeared after CD34 ϩ selection. Interestingly, a negative PCR was achieved in 11 of 15 separation runs (73%) in patients with FL, whereas in patients with MCL and B-CLL/IC only five of nine (55%) and four of 13 runs (31%), respectively, resulted in a final product negative for the molecular marker (P = 0.025 for FL vs B-CLL).
A unique result was observed in a single patient whose leukapheresis product was contaminated with 3.1% B-CLL cells prior to purging. Immunoselection with the Isolex 300SA system was associated with a nonspecific enrichment of CD19 ϩ CD5 ϩ CD34 Ϫ leukemic cells to 31% in the final preparation with the remaining 69% being CD34 ϩ CD19 Ϫ progenitor cells. In order to obtain a tumorfree graft, this patient underwent a second cycle of mobilization yielding a PBPC graft which was successfully purged by negative immunomagnetic depletion with B cell antibodies.
Myeloablative therapy, PBPC reinfusion, and hematopoietic engraftment
One patient with FL who was refractory to Dexa-BEAM and subsequent radiotherapy was considered ineligible for high-dose therapy. All others achieved minimal disease after two cycles of Dexa-BEAM or additional salvage chemotherapy and proceeded to myeloblative therapy with TBI/CY followed by PBPC reinfusion. Twenty patients were autografted with selected CD34 ϩ cells only, three patients received unmanipulated back-up in addition to purified cells because of low CD34 ϩ cell numbers in the immunoselected products, a single patient who had mobilized poorly was reconstituted with unpurged PBPC and autologous BM, and the remaining patient received negatively depleted PBPC as described above. Reinfusion of CD34 ϩ selected products alone resulted in prompt engraftment in all 20 cases (neutrophils Ͼ0.5 ϫ 10 9 /l after 9 (8-10) and platelets Ͼ20 ϫ 10 9 /l after 10 (8-18) days, respectively).
Outcome and molecular follow-up
Five (two FL and three MCL) of the 20 patients autografted with CD34 ϩ selected cells alone relapsed 4, 6, 12, 19 and 36 months post-transplant. The two patients with FL succumbed to their progressive lymphomas at 4 and 24 months, respectively, whereas the remaining 18 patients are alive with a median follow-up of 28 (19-42) months.
All patients were available for prospective molecular monitoring using PCR amplification of t(14;18) (n = 4) or clonal CDRIII rearrangements (n = 16). The two patients 157 Table 2 Results of CD34 ϩ selection relapsing early never lost their specific t(14;18) signal and CDRIII clonality, respectively, while disease recurrence in the three patients with MCL, who initially showed a polyclonal CDRIII pattern, was accompanied by reappearance of clonality. All other patients are in continuous molecular remission with the exception of a single patient (B-CLL) whose leukemia-specific CDRIII signal has been persistently present up to 19 months post-reinfusion of immunoselected PBPC.
Long-term hematopoietic recovery
Sixteen patients reinfused with immunoselected PBPC alone were available for monitoring of long-term hematopoietic and immune recovery. Patients who had experienced early relapse or had received intravenous immunoglobulin were excluded. All patients showed durable hematopoietic engraftment as indicated by stable and steadily increasing platelet counts (Table 3) . At 12 months posttransplant, normal platelet levels (Ͼ150 ϫ 10 9 /l) were observed in 13 of 16 individuals (81%).
Serological immune recovery
Serum IgG levels were slightly subnormal in 50% of the patients at 3 months post-PBPCT. This fraction decreased to 20% at 6 and 12 months. A reduced 12-month IgA level was recorded in only one of 15 patients with data available (7%).
As revealed by serology, specific immunity to measles was present in each individual patient when tested 1 year post-transplant or later. There was no evidence for an active measles infection during the observation period in any patient.
Kinetics of platelet counts and serological markers of immune function were similar to those of 12 patients with low-grade lymphoma who had received myeloablative therapy with autografting of unmanipulated PBPC during the same time. However, these patients did not fulfil the inclusion criteria for participation in the study or refused inclusion and are therefore not perfectly comparable (Tables 3 and 4) .
Oligoclonal bands
Immunofixation electrophoresis identified a monoclonal or oligoclonal gammopathy in seven of the 16 study patients investigated (Table 4) . Paraproteins occurred at 3 to 6 months post-transplant and disappeared during longer follow-up in almost all instances. The following subclasses were observed: IgG kappa, IgM kappa (UPN P209, FL); IgG kappa, IgG lambda (P239, MCL); IgG lambda (P256, B-CLL); IgM kappa, IgG lambda (P263, MCL); IgA kappa, IgG lambda, IgG lambda (P278, FL); IgG kappa, IgG kappa (P307, IC); IgG kappa (P312, MCL). Only one of these patients (P307) had a paraprotein prior to transplant (IgM kappa) which was detectable also post-transplant in addition to the described bands. In patient P209, a pronounced biclonal gammopathy with peak paraprotein levels of 26.2 g/l for IgG and 8.8 g/l for IgM developed 3 months after PBPCT and was associated with an immune hemolytic anemia requiring prednisolone treatment. Paraproteinemia and hemolysis had completely resolved at month ϩ12. In addition to this case, we observed an autoimmune event in patient P238 who acquired immune thyroiditis 27 months post-transplant.
Lymphocyte subsets
Whereas CD3
ϩ CD8 ϩ T cells and CD56 ϩ CD3 Ϫ NK cells reached relatively high levels already at 3 months posttransplant which did not change much during the further course, B cells, total CD3
ϩ T cells and CD3 ϩ CD4 ϩ T cells were still reduced at 3 months but showed a steady increase during longer follow-up (Figure 1) . At 3 months post-transplant, 10 of 14 patients (= 71%, compared to 3/9 = 33% of the control patients; P = 0.073) had CD3 ϩ CD4 ϩ counts below 250/l. This fraction was reduced to three of 16 at 1 year (= 19%; control patients, two of 11 = 18%). Although statistical significance was not reached, the median 158 
CD3
ϩ CD4 ϩ count at 3 months tended to be lower in the study group than in the control group (171 (50-1159) vs 277 (106-573)/l). This difference was mainly due to a pronounced reduction of the CD3 ϩ CD4 ϩ CD45RA ϩ T cells ('naive' T cells) which were virtually absent during the first 3 months in the study group (absolute numbers 6 (0-164)/l vs 79 (3-310)/l; P = 0.03, and relative numbers 3.5 (0-30)% vs 28 (1-54)%; P = 0.056, in study vs control patients, respectively). However, with subsequent recovery of CD3 ϩ CD4 ϩ CD45RA ϩ cells, these differences vanished (median percentage 9 and 16% of total CD4 ϩ T cells in the study group at 6 and 12 months, respectively; Figure 1) .
Infections
Severe or life-threatening infections did not occur during initial cytopenia or the first 12 months of follow-up. Altogether, seven infectious episodes were recorded in the immunoselected 16 patients after complete hematopoietic recovery during the first post-transplant year (Table 4) . Three patients had an episode of symptomatic Herpes zoster infection after having stopped aciclovir prophylaxis, one patient suffered from topical candidiasis, one from chronic sinusitis, one from C. difficile colitis (all responding to specific therapy), and the remaining episode was grade 2 fever of unknown origin resolving after empiric antibacterial treatment. The four episodes in the control patients were: one case of Herpes zoster infection, two cases of local Herpes simplex infection, and one case of topical mycosis.
Discussion
This prospective study shows that highly purified CD34 ϩ PBPC can be produced with the Isolex 300 system. With 89%, the median purity achieved by immunomagnetic selection appears to be superior to the data reported for immunoadsorption of CD34 ϩ PBPC 7, 8, 18 but similar to those observed with the Isolex system in previous trials. [9] [10] [11] When switching to the fully automated Isolex 300i device, we were able to further increase these results, reaching at least 92% purity with every single run (median 99%). This improvement could be due to the selection system itself, but also may have to do with gain of operators' experience and with selection bias, as the products subjected to Isolex 300i separation had favorable preselection characteristics (Table 2) . However, comparably excellent purities were observed using the Isolex 300i device outside this study with poorer starting material. 19 Although the recoveries of CD34 ϩ cells were relatively low in the present series they were, at least for the Isolex 300i runs, within the range reported for the immunoadsorption technique. 8, 18 In the setting investigated here, high CD34 ϩ cell purity is only important if it translates into effective purging of tumor cells. With regard to patients with FL, PCR-documented lymphoma cell contamination could be eliminated in 11 of 15 separation runs. This appears to be no worse than the findings of two recent studies on immunoadsorption of CD34 ϩ PBPC, which resulted in CDRIII/t(14;18) PCR negativity in 33% and 60%, respectively, of the patients studied. 7, 8 However, immunomagnetic CD34 selection was less effective in purging tumor cells below the level of PCR detection in our patients with MCL or B-CLL. This might be due to a higher preselection graft contamination or caused by disease-specific characteristics of the tumor cells, eg increased unspecific adhesion of lymphoma cells to the sheep-IgG-coated immunobeads, which probably accounted for the surprising relative B-CLL cell enrichment observed in patient P206. Nevertheless, the median lymphoma cell depletion in the patients without complete FACS negativity was 3.2 log and thus, seems to be comparable to the data obtained in patients with breast cancer. 9 If more effective purging is required, as in most patients with B-CLL, a combination of the Isolex procedure with negative selection steps can be performed which allows elimination of up to 6 logs of unwanted B cells. 19 This strategy also helps to circumvent the problem of possible CD34 ϩ 'tumor stem cells'. Hematopoietic engraftment after myeloablative treatment and reinfusion of highly purified PBPC was durable. This finding refutes earlier speculations that accessory cells might be necessary for reconstitution of hematopoiesis 20 and is in line with the sustained donor chimerism seen after allogeneic transplantation of Isolex-selected stem cells. 21 The control group used in this study was not optimally matched due to selection bias. Nevertheless, in spite of the very low lymphocyte content of the stem cell graft (median T cell count 0.4 ϫ 10 5 /kg), cellular, serological and clinical parameters of immune recovery of the study patients were not very different from those observed in these controls or in recipients of unmanipulated autografts investigated elsewhere. [22] [23] [24] [25] However, an intriguing peculiarity of the patients receiving purified grafts was the very low number of CD4 ϩ CD45RA ϩ ('naive') T cells during the first months post-transplant. This observation parallels findings reported for recipients of T cell-depleted allografts 26 and confirms that in adults T cell recovery after high-dose therapy is mainly due to expansion of mature T cells transferred with the graft or surviving in the recipient, but not to thymusdependent maturation of lymphoid progenitor cells (which should result in increased frequencies of CD4 ϩ CD45RA ϩ T cells). 27, 28 Furthermore, our data suggest that the rapid T cell repopulation from very limited T cell numbers after autografting with CD34 ϩ selected PBPC predominantly relies on amplification of the CD4 ϩ CD45RO ϩ cell com-partment (activated or memory T cells), whereas the thousand-fold higher T cell number reinfused with unmanipulated grafts gives rise to expansion of both CD4 ϩ CD45RA ϩ and CD4 ϩ CD45RO ϩ T cells. This means that CD4 ϩ CD45RA ϩ cells might also be generated by a thymus-independent pathway. These hypotheses are in accordance with recent observations in a small number of patients autografted with virtually T cell-free PBPC graft (mean T cell count 0.04 ϫ 10 5 /kg) showing strongly reduced numbers of CD4 ϩ T cells and CD45RA ϩ T cells in the peripheral blood during the first 6 months after transplant. 29 Rapid expansion of T lymphocytes from a low number of surviving or retransfused cells should be associated with a restricted T cell receptor diversity of the reconstituted T cell population. 28, 29 Although we did not analyze the T cell repertoire directly, the frequent occurrence of transient clonal gammopathies indicates that lymphocyte diversity may indeed have been limited during the first post-transplant months after CD34 ϩ cell transplantation. Similarly, the incidence of gammopathies is increased in recipients of T cell-depleted grafts or in patients with disturbed T cell function after allogeneic BMT. 30 Transient abnormal clonal protein bands have been observed also in small fractions of patients with B cell neoplasia after autologous stem cell transplantation with unpurged grafts. 31 In comparison to these findings, our data suggest that the incidence of clonal gammopathies might be considerably increased after heavily T and B cell-depleted autotransplants. The clinical impact of these phenomena, however, appears to be limited, as in the present series there was no apparent difference between study and control patients in terms of infections. These results obtained with highly purified CD34 ϩ cells and fully myeloablative highdose therapy confirm and extend the findings of another recent study on CD34 ϩ selection using the immunoadsorption system which provides less intensive lymphocyte depletion. 18 Interestingly, the specific measles titer was not lost in a single case after CD34 ϩ -selected PBPCT, suggesting that even the intense in vivo and ex vivo elimination of T and B cells performed here does not eradicate immune memory acquired prior to high-dose therapy. This observation leads to two conclusions: (1) like the situation after autotransplantation of unmanipulated bone marrow, immunity to measles persists after autografting of lymphocyte-depleted stem cells at least in adult patients who have undergone natural measles infection, 32 which has obvious implications for vaccination needs after transplant; (2) myeloblative treatment with reinfusion of highly purified CD34 ϩ PBSC is not truly immunoablative, suggesting that the value of this approach for the treatment of autoimmune diseases might be limited. 33 Whether, on the contrary, the transient clonal dysregulation of the immune system frequently observed in our patients gives rise to new autoimmune phenomena after stem cell transplantation remains to be settled. 34 Taken together, our data demonstrate that CD34 ϩ selection with the Isolex system allows preparation of highly purified CD34 ϩ fractions and effective tumor cell depletion. The CD34 ϩ products can be reinfused safely after myeloablative treatment and result in rapid hematopoietic recovery. CD34 ϩ selection does not appear to affect longterm hematopoietic and immune reconstitution although the clinical impact of the delayed recovery of CD4 ϩ CD45RA ϩ T cells and the occurrence of transient clonal gammopathies remains to be clarified. The fact that all patients retained their specific measles immunity suggests that myeloablative treatment with reinfusion of highly purified CD34 ϩ PBPC is not immunoablative.
